Showing results (11-20 of 61) with videos related to
Sort By:
Pageof 7
British Journal of Haematology|November 28, 2008
Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosisMark A Scheper, Ashraf Badros, Risa Chaisuparat, et al.Clinical Lymphoma|March 30, 2005
Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemiaMorie A Gertz, Susan M Geyer, Ashraf Badros, et al.British Journal of Haematology|April 8, 2017
Marizomib for central nervous system-multiple myelomaAshraf Badros, Zeba Singh, Binod Dhakal, et al.Transfusion|March 16, 2002
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioningAshraf Badros, Guido Tricot, Amir Toor, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 5, 2009
A novel bioassay model to determine clinically significant bisphosphonate levelsMark A Scheper, Ashraf Badros, Andrew R Salama, et al.Clinical Lymphoma & Myeloma|January 19, 2007
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myelomaAshraf Badros, Olga Goloubeva, Robert Fenton, et al.Archives of Dermatology|February 24, 2006
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitorsApril Deng, Valerie Harvey, Bahram Sina, et al.Cancer|July 27, 2007
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literatureAshraf Badros, Olga Goloubeva, Jay S Dalal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factorsAshraf Badros, Dianna Weikel, Andrew Salama, et al.Annals of Hematology|October 8, 2013
Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignanciesBhavana Bhatnagar, Aaron P Rapoport, Hong-Bin Fang, et al.Pageof 7